TVA Medical is an Austin, Texas-based medical device company developing minimally invasive therapies for chronic kidney disease and other medical conditions. Its core product is a catheter-based system that uses an endovascular approach to create an arteriovenous fistula (AVF) by joining an artery to a vein in patients who require hemodialysis. The company's technology provides vascular access to connect patients to dialysis machines. Led by president and CEO Adam Berman, TVA Medical is advancing clinical and market development work. The company received a $7M credit facility from Square 1 Bank to fund global clinical and market development initiatives. The financing was reported by FinSMEs on December 14, 2016. TVA Medical, based in Austin, Texas and led by president & CEO Adam L. Berman, develops the everlinQ™ endoAVF System, a catheter-based technology to create hemodialysis access for chronic kidney disease patients. The system uses two thin, flexible magnetic catheters inserted into an artery and vein in the arm; a small burst of radiofrequency energy connects the vessels to create a fistula and the catheters are removed. The device has been studied outside the United States and has received CE mark but is not available in the United States and has not been approved by the U.S. Food and Drug Administration for commercial use. TVA completed a $15M Series C financing and intends to use the funds to continue clinical activities and accelerate market development for the everlinQ system. The capital will support the ongoing clinical study (a 12-month follow up scheduled to complete in 2016) and additional global clinical research. Funds will also be used for device reimbursement and market-access initiatives. TVA Medical, founded in 2008 and based in Austin, Texas, develops a minimally invasive catheter-based system that allows physicians to create an arteriovenous fistula to deliver hemodialysis to patients with end-stage renal disease. The technology is being studied outside the United States and is currently not available in the U.S. The company raised $9.5M in a Series B financing led by S3 Ventures, with participation from TriStar Technology Ventures and existing investor Santé Ventures. TVA intends to use the funds to further validate its endovascular technology and complete additional clinical studies to support worldwide regulatory approvals. The company was founded by Santé Ventures, William (Billy) E. Cohn, MD, and CEO Adam L. Berman. TVA plans to seek Food and Drug Administration clearance in the future. TVA Medical is an Austin, Texas–based medical device company focused on developing minimally invasive therapies for end-stage renal disease (ESRD). The company was formed in partnership with founder William (Billy) Cohn, MD, a cardiovascular surgeon and Director of Minimally Invasive Surgical Technology at the Texas Heart Institute. TVA plans to complete product development and to conduct human clinical trials using the proceeds from its recent financing. TVA raised $2.6M in a Series A investment from early-stage life science venture capital firm Santé Ventures. In conjunction with the financing, Adam Berman will join TVA as CEO, and Santé’s Cunningham and Kevin Lalande will serve on TVA’s board of directors. Cohn has also joined Santé Ventures as a Venture Partner.

Total raised

$34M

Funding rounds

4

Latest round

Debt Financing

Latest activity

Dec 2016